In silico screening of potential agonists of a glucagon-like peptide-1 receptor among female sex hormone derivatives

References

• Alomar, S. A., Găman, M. A., Prabahar, K., Arafah, O. A., Almarshood, F., Baradwan, S., Aboudi, S. A. S., Abuzaid, M., Almubarki, A. A. M. A., Alomar, O., Al-Badawi, I. A., Salem, H., & Abu-Zaid, A. (2022). The effect of tamoxifen on the lipid profile in women: A systematic review and meta-analysis of randomized controlled trials. Experimental Gerontology, 159, 111680. https://doi.org/10.1016/j.exger.2021.111680
   PubMed Web of Science ®Google Scholar
• Ambery, P., Parker, V. E., Stumvoll, M., Posch, M. G., Heise, T., Plum-Moerschel, L., Tsai, L. F., Robertson, D., Jain, M., Petrone, M., Rondinone, C., Hirshberg, B., & Jermutus, L. (2018). MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: A randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet (London, England), 391(10140), 2607–2618. https://doi.org/10.1016/S0140-6736(18)30726-8
   PubMed Web of Science ®Google Scholar
• Amiri, M., Ramezani Tehrani, F., Nahidi, F., Kabir, A., Azizi, F., & Carmina, E. (2017). Effects of oral contraceptives on metabolic profile in women with polycystic ovary syndrome: A meta-analysis comparing products containing cyproterone acetate with third generation progestins. Metabolism: Clinical and Experimental, 73, 22–35. https://doi.org/10.1016/j.metabol.2017.05.001
   PubMed Web of Science ®Google Scholar
• An, K. C. (2016). Selective estrogen receptor modulators. Asian Spine Journal, 10(4), 787–791. https://doi.org/10.4184/asj.2016.10.4.787
   PubMedGoogle Scholar
• Barrera, J., Chambliss, K. L., Ahmed, M., Tanigaki, K., Thompson, B., McDonald, J. G., Mineo, C., & Shaul, P. W. (2014). Bazedoxifene and conjugated estrogen prevent diet-induced obesity, hepatic steatosis, and type 2 diabetes in mice without impacting the reproductive tract. American Journal of Physiology-Endocrinology and Metabolism, 307(3), E345–E354. https://doi.org/10.1152/ajpendo.00653.2013
   PubMed Web of Science ®Google Scholar
• Barrett-Connor, E., Ensrud, K. E., Harper, K., Mason, T. M., Sashegyi, A., Krueger, K. A., & Anderson, P. W. (2003). Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes. Clinical Therapeutics, 25(3), 919–930. https://doi.org/10.1016/s0149-2918(03)80114-5
   PubMed Web of Science ®Google Scholar
• Bhattacharya, S. M., & Jha, A. (2012). Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome. Fertility and Sterility, 98(4), 1053–1059. https://doi.org/10.1016/j.fertnstert.2012.06.035
   PubMed Web of Science ®Google Scholar
• Britton, L. E., Alspaugh, A., Greene, M. Z., & McLemore, M. R. (2020). CE: An evidence-based update on contraception. The American Journal of Nursing, 120(2), 22–33. https://doi.org/10.1097/01.NAJ.0000654304.29632.a7
   PubMed Web of Science ®Google Scholar
• Cena, H., Chiovato, L., & Nappi, R. E. (2020). Obesity, polycystic ovary syndrome, and infertility: A new avenue for GLP-1 receptor agonists. The Journal of Clinical Endocrinology and Metabolism, 105(8), e2695–e2709. https://doi.org/10.1210/clinem/dgaa285
   PubMed Web of Science ®Google Scholar
• Choi, Y. J., Bak, K., Yeo, Y., Choi, Y., & Shin, S. (2021). Incident type 2 diabetes risk of selective estrogen receptor modulators in female patients with breast cancer. Pharmaceuticals (Basel, Switzerland), 14(9), 925. https://doi.org/10.3390/ph14090925
   PubMedGoogle Scholar
• Cucciniello, L., Gerratana, L., Del Mastro, L., & Puglisi, F. (2022). Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long? Cancer Treatment Reviews, 110, 102445. https://doi.org/10.1016/j.ctrv.2022.102445
   PubMed Web of Science ®Google Scholar
• Deming, S. N., Michotte, Y., Massart, D. L., Kaufman, L., & Vandeginste, B. G. M. (1988). Chemometrics -A textbook (1st ed.). Elsevier Science. ISBN: 9780444426604.
   Google Scholar
• Drucker, D. J., & Nauck, M. A. (2006). The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet (London, England), 368(9548), 1696–1705. https://doi.org/10.1016/S0140-6736(06)69705-5
   PubMed Web of Science ®Google Scholar
• Foidart, J. M., & Faustmann, T. (2007). Advances in hormone replacement therapy: Weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen. Gynecological Endocrinology, 23(12), 692–699. https://doi.org/10.1080/09513590701582323
   PubMed Web of Science ®Google Scholar
• Frisch, M. J., Trucks, G. W., Schlegel, H. B., Scuseria, G. E., Robb, M. A., Cheeseman, J. R., Scalmani, G., Barone, V., Mennucci, B., Petersson, G. A., Nakatsuji, H., Caricato, M., Li, X., Hratchian, H. P., Izmaylov, A. F., Bloino, J., Zheng, G., Sonnenberg, J. L., Hada, M., … Fox, D. J. (2009). Gaussian 09, Revision D.01. Gaussian, Inc.
   Google Scholar
• Gialeraki, A., Valsami, S., Pittaras, T., Panayiotakopoulos, G., & Politou, M. (2018). Oral contraceptives and HRT risk of thrombosis. Clinical and Applied Thrombosis/Hemostasis, 24(2), 217–225. https://doi.org/10.1177/1076029616683802
   PubMed Web of Science ®Google Scholar
• Grover-Páez, F., Zavalza-Gómez, A. B., & Anaya-Prado, R. (2013). Raloxifene modifies the insulin sensitivity and lipid profile of postmenopausal insulin resistant women. Gynecological Endocrinology, 29(7), 674–677. https://doi.org/10.3109/09513590.2013.788628
   PubMed Web of Science ®Google Scholar
• Guillaume, M., Handgraaf, S., Fabre, A., Raymond-Letron, I., Riant, E., Montagner, A., Vinel, A., Buscato, M., Smirnova, N., Fontaine, C., Guillou, H., Arnal, J. F., & Gourdy, P. (2017). Selective activation of estrogen receptor α activation function-1 is sufficient to prevent obesity, steatosis, and insulin resistance in mouse. The American Journal of Pathology, 187(6), 1273–1287. https://doi.org/10.1016/j.ajpath.2017.02.013
   PubMed Web of Science ®Google Scholar
• Hinnen, D. (2017). Glucagon-like peptide 1 receptor agonists for type 2 diabetes. Diabetes Spectrum, 30(3), 202–210. https://doi.org/10.2337/ds16-0026
   PubMedGoogle Scholar
• Jensterle, M., Janez, A., Fliers, E., DeVries, J. H., Vrtacnik-Bokal, E., & Siegelaar, S. E. (2019). The role of glucagon-like peptide-1 in reproduction: From physiology to therapeutic perspective. Human Reproduction Update, 25(4), 504–517. https://doi.org/10.1093/humupd/dmz019
   PubMed Web of Science ®Google Scholar
• Johansson, H., Gandini, S., Guerrieri-Gonzaga, A., Iodice, S., Ruscica, M., Bonanni, B., Gulisano, M., Magni, P., Formelli, F., & Decensi, A. (2008). Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer. Cancer Research, 68(22), 9512–9518. https://doi.org/10.1158/0008-5472.CAN-08-0553
   PubMed Web of Science ®Google Scholar
• Junge, W., El-Samalouti, V., Gerlinger, C., & Schaefers, M. (2009). Effects of menopausal hormone therapy on hemostatic parameters, blood pressure, and body weight: Open-label comparison of randomized treatment with estradiol plus drospirenone versus estradiol plus norethisterone acetate. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 147(2), 195–200. https://doi.org/10.1016/j.ejogrb.2009.09.004
   PubMed Web of Science ®Google Scholar
• Karlsson, S., Hirsimäki, Y., Mäntylä, E., Nieminen, L., Kangas, L., Hirsimäki, P., Perry, C. J., Mulhern, M., Millar, P., Handa, J., & Williams, G. M. (1996). A two-year dietary carcinogenicity study of the antiestrogen toremifene in Sprague-Dawley rats. Drug and Chemical Toxicology, 19(4), 245–266. https://doi.org/10.3109/01480549608998236
   PubMed Web of Science ®Google Scholar
• Katritch, V., Cherezov, V., & Stevens, R. C. (2013). Structure-function of the G protein-coupled receptor superfamily. Annual Review of Pharmacology and Toxicology, 53(1), 531–556. https://doi.org/10.1146/annurev-pharmtox-032112-135923
   PubMed Web of Science ®Google Scholar
• Khosrow-Khavar, F., Filion, K. B., Al-Qurashi, S., Torabi, N., Bouganim, N., Suissa, S., & Azoulay, L. (2017). Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: A systematic review and meta-analysis of randomized controlled trials. Annals of Oncology, 28(3), 487–496. https://doi.org/10.1093/annonc/mdw673
   PubMed Web of Science ®Google Scholar
• Kimura, T., Pydi, S. P., Pham, J., & Tanaka, N. (2020). Metabolic functions of G protein-coupled receptors in hepatocytes-Potential applications for diabetes and NAFLD. Biomolecules, 10(10), 1445. https://doi.org/10.3390/biom10101445
   PubMed Web of Science ®Google Scholar
• Kuang, Z. K., Cheng, X. Y., Yang, Z. X., Guo, Y. X., Huang, Y. Q., & Su, Z. D. (2021). In silico prediction of GLP-1R agonists using machine learning approach. Chemical Papers, 75(7), 3587–3598. https://doi.org/10.1007/s11696-021-01600-3
   Web of Science ®Google Scholar
• Land, S. R., Wickerham, D. L., Costantino, J. P., Ritter, M. W., Vogel, V. G., Lee, M., Pajon, E. R., Wade, J. L., 3rd, Dakhil, S., Lockhart, J. B., Jr., Wolmark, N., & Ganz, P. A. (2006). Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA, 295(23), 2742–2751. https://doi.org/10.1001/jama.295.23.joc60075
   PubMed Web of Science ®Google Scholar
• Li, J., Ren, J., & Sun, W. (2017). A comparative systematic review of Yasmin (drospirenone pill) versus standard treatment options for symptoms of polycystic ovary syndrome. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 210, 13–21. https://doi.org/10.1016/j.ejogrb.2016.11.013
   PubMed Web of Science ®Google Scholar
• Liao, H. J., & Tzen, J. T. C. (2022). Investigating potential GLP-1 receptor agonists in cyclopeptides from Pseudostellaria heterophylla, Linum usitatissimum, and Drymaria diandra, and peptides derived from Heterophyllin B for the treatment of type 2 diabetes: An in silico study. Metabolites, 12(6), 549. https://doi.org/10.3390/metabo12060549
   PubMed Web of Science ®Google Scholar
• Liu, C. L., & Yang, T. L. (2003). Sequential changes in serum triglyceride levels during adjuvant tamoxifen therapy in breast cancer patients and the effect of dose reduction. Breast Cancer Research and Treatment, 79(1), 11–16. https://doi.org/10.1023/a:1023348021773
   PubMed Web of Science ®Google Scholar
• Manson, J. E., Chlebowski, R. T., Stefanick, M. L., Aragaki, A. K., Rossouw, J. E., Prentice, R. L., Anderson, G., Howard, B. V., Thomson, C. A., LaCroix, A. Z., Wactawski-Wende, J., Jackson, R. D., Limacher, M., Margolis, K. L., Wassertheil-Smoller, S., Beresford, S. A., Cauley, J. A., Eaton, C. B., Gass, M., … Wallace, R. B. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA, 310(13), 1353–1368. https://doi.org/10.1001/jama.2013.278040
   PubMed Web of Science ®Google Scholar
• Massart, D. L. (1989). The interpretation of analytical chemical data by the use of cluster analysis. Wiley. ISBN 978-089-464-358-3.
   Google Scholar
• Massart, D. L., & Vandeginste, B. G. (1998). Handbook of chemometrics and qualimetrics: Part B. Elsevier. ISBN 978-044-482-853-8.
   Google Scholar
• Moon, M. J., Park, S., Kim, D. K., Cho, E. B., Hwang, J. I., Vaudry, H., & Seong, J. Y. (2012). Structural and molecular conservation of glucagon-like peptide-1 and its receptor confers selective ligand-receptor interaction. Frontiers in Endocrinology, 3, 141. https://doi.org/10.3389/fendo.2012.00141
   PubMedGoogle Scholar
• Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., Holst, J. J., Langhans, W., Meier, J. J., Nauck, M. A., Perez-Tilve, D., Pocai, A., Reimann, F., Sandoval, D. A., Schwartz, T. W., … Tschöp, M. H. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72–130. https://doi.org/10.1016/j.molmet.2019.09.010
   PubMed Web of Science ®Google Scholar
• Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes - State-of-the-art. Molecular Metabolism, 46, 101102. https://doi.org/10.1016/j.molmet.2020.101102
   PubMed Web of Science ®Google Scholar
• Nguyen, M. C., Stewart, R. B., Banerji, M. A., Gordon, D. H., & Kral, J. G. (2001). Relationships between tamoxifen use, liver fat and body fat distribution in women with breast cancer. International Journal of Obesity and Related Metabolic Disorders, 25(2), 296–298. https://doi.org/10.1038/sj.ijo.0801488
   PubMed Web of Science ®Google Scholar
• Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014). GLP-1 receptor localization in monkey and human tissue: Novel distribution revealed with extensively validated monoclonal antibody. Endocrinology, 155(4), 1280–1290. https://doi.org/10.1210/en.2013-1934
   PubMed Web of Science ®Google Scholar
• Redij, T., Ma, J., Li, Z., Hua, X., & Li, Z. (2019). Discovery of a potential positive allosteric modulator of glucagon-like peptide 1 receptor through virtual screening and experimental study. Journal of Computer-Aided Molecular Design, 33(11), 973–981. https://doi.org/10.1007/s10822-019-00254-4
   PubMed Web of Science ®Google Scholar
• Rey, J. R., Cervino, E. V., Rentero, M. L., Crespo, E. C., Alvaro, A. O., & Casillas, M. (2009). Raloxifene: Mechanism of action, effects on bone tissue, and applicability in clinical traumatology practice. The Open Orthopaedics Journal, 3(1), 14–21. https://doi.org/10.2174/1874325000903010014
   PubMedGoogle Scholar
• Rohatgi, N., Blau, R., & Lower, E. E. (2002). Raloxifene is associated with less side effects than tamoxifen in women with early breast cancer: A questionnaire study from one physician’s practice. Journal of Women’s Health & Gender-Based Medicine, 11(3), 291–301. https://doi.org/10.1089/152460902753668484
   PubMedGoogle Scholar
• Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018). Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function. Frontiers in Endocrinology, 9, 672. https://doi.org/10.3389/fendo.2018.00672
   PubMed Web of Science ®Google Scholar
• Sánchez-Garrido, M. A., Brandt, S. J., Clemmensen, C., Müller, T. D., DiMarchi, R. D., & Tschöp, M. H. (2017). GLP-1/glucagon receptor co-agonism for treatment of obesity. Diabetologia, 60(10), 1851–1861. https://doi.org/10.1007/s00125-017-4354-8
   PubMed Web of Science ®Google Scholar
• Saquib, N., Flatt, S. W., Natarajan, L., Thomson, C. A., Bardwell, W. A., Caan, B., Rock, C. L., & Pierce, J. P. (2007). Weight gain and recovery of pre-cancer weight after breast cancer treatments: Evidence from the women’s healthy eating and living (WHEL) study. Breast Cancer Research and Treatment, 105(2), 177–186. https://doi.org/10.1007/s10549-006-9442-2
   PubMed Web of Science ®Google Scholar
• Schindler, A. E., Campagnoli, C., Druckmann, R., Huber, J., Pasqualini, J. R., Schweppe, K. W., & Thijssen, J. H. (2003). Classification and pharmacology of progestins. Maturitas, 46(Suppl 1), S7–S16. https://doi.org/10.1016/j.maturitas.2003.09.014
   PubMed Web of Science ®Google Scholar
• Shen, H. H., Yang, C. Y., Kung, C. W., Chen, S. Y., Wu, H. M., Cheng, P. Y., Lam, K. K., & Lee, Y. M. (2019). Raloxifene inhibits adipose tissue inflammation and adipogenesis through Wnt regulation in ovariectomized rats and 3 T3-L1 cells. Journal of Biomedical Science, 26(1), 62. https://doi.org/10.1186/s12929-019-0556-3
   PubMed Web of Science ®Google Scholar
• Silva-Bermudez, L. S., Toloza, F. J. K., Perez-Matos, M. C., de Souza, R. J., Banfield, L., Vargas-Villanueva, A., & Mendivil, C. O. (2020). Effects of oral contraceptives on metabolic parameters in adult premenopausal women: A meta-analysis. Endocrine Connections, 9(10), 978–998. https://doi.org/10.1530/EC-20-0423
   PubMed Web of Science ®Google Scholar
• Song, D., Hu, Y., Diao, B., Miao, R., Zhang, B., Cai, Y., Zeng, H., Zhang, Y., & Hu, X. (2021). Effects of tamoxifen vs. toremifene on fatty liver development and lipid profiles in breast cancer. BMC Cancer, 21(1), 798. https://doi.org/10.1186/s12885-021-08538-5
   PubMed Web of Science ®Google Scholar
• Sriram, K., & Insel, P. A. (2018). G protein-coupled receptors as targets for approved drugs: How many targets and how many drugs? Molecular Pharmacology, 93(4), 251–258. https://doi.org/10.1124/mol.117.111062
   PubMed Web of Science ®Google Scholar
• Stanczyk, F. Z., Archer, D. F., & Bhavnani, B. R. (2013). Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: Pharmacokinetics, pharmacodynamics and risk assessment. Contraception, 87(6), 706–727. https://doi.org/10.1016/j.contraception.2012.12.011
   PubMed Web of Science ®Google Scholar
• Swedberg, J. E., Schroeder, C. I., Mitchell, J. M., Durek, T., Fairlie, D. P., Edmonds, D. J., Griffith, D. A., Ruggeri, R. B., Derksen, D. R., Loria, P. M., Liras, S., Price, D. A., & Craik, D. J. (2015). Cyclic alpha-conotoxin peptidomimetic chimeras as potent GLP-1R agonists. European Journal of Medicinal Chemistry, 103, 175–184. https://doi.org/10.1016/j.ejmech.2015.08.046
   PubMed Web of Science ®Google Scholar
• Teal, S., & Edelman, A. (2021). Contraception selection, effectiveness, and adverse effects: A review. JAMA, 326(24), 2507–2518. https://doi.org/10.1001/jama.2021.21392
   PubMed Web of Science ®Google Scholar
• Tee, M. K., Rogatsky, I., Tzagarakis-Foster, C., Cvoro, A., An, J., Christy, R. J., Yamamoto, K. R., & Leitman, D. C. (2004). Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta. Molecular Biology of the Cell, 15(3), 1262–1272. https://doi.org/10.1091/mbc.e03-06-0360
   PubMed Web of Science ®Google Scholar
• Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455–461. https://doi.org/10.1002/jcc.21334
   PubMed Web of Science ®Google Scholar
• Vacurova, E., Trnovska, J., Svoboda, P., Skop, V., Novosadova, V., Reguera, D. P., Petrezselyová, S., Piavaux, B., Endaya, B., Spoutil, F., Zudova, D., Stursa, J., Melcova, M., Bielcikova, Z., Werner, L., Prochazka, J., Sedlacek, R., Huttl, M., Hubackova, S. S., … Neuzil, J. (2022). Mitochondrially targeted tamoxifen alleviates markers of obesity and type 2 diabetes mellitus in mice. Nature Communications, 13(1), 1866. https://doi.org/10.1038/s41467-022-29486-z
   PubMed Web of Science ®Google Scholar
• Vasighi, M., Romanova, J., & Nedyalkova, M. (2022). A multilevel approach for screening natural compounds as an antiviral agent for COVID-19. Computational Biology and Chemistry, 98, 107694. https://doi.org/10.1016/j.compbiolchem.2022.107694
   PubMed Web of Science ®Google Scholar
• Wallen, W. J., Belanger, M. P., & Wittnich, C. (2001). Sex hormones and the selective estrogen receptor modulator tamoxifen modulate weekly body weights and food intakes in adolescent and adult rats. The Journal of Nutrition, 131(9), 2351–2357. https://doi.org/10.1093/jn/131.9.2351
   PubMed Web of Science ®Google Scholar
• Wang, J., Yang, D., Cheng, X., Yang, L., Wang, Z., Dai, A., Cai, X., Zhang, C., Yuliantie, E., Liu, Q., Jiang, H., Liu, H., Wang, M. W., & Yang, H. (2021). Allosteric modulators enhancing GLP-1 binding to GLP-1R via a transmembrane site. ACS Chemical Biology, 16(11), 2444–2452. https://doi.org/10.1021/acschembio.1c00552
   PubMed Web of Science ®Google Scholar
• Wasserman, L., Flatt, S. W., Natarajan, L., Laughlin, G., Matusalem, M., Faerber, S., Rock, C. L., Barrett-Connor, E., & Pierce, J. P. (2004). Correlates of obesity in postmenopausal women with breast cancer: Comparison of genetic, demographic, disease-related, life history and dietary factors. International Journal of Obesity and Related Metabolic Disorders, 28(1), 49–56. https://doi.org/10.1038/sj.ijo.0802481
   PubMed Web of Science ®Google Scholar
• Yang, F., Li, N., Gaman, M. A., & Wang, N. (2021). Raloxifene has favorable effects on the lipid profile in women explaining its beneficial effect on cardiovascular risk: A meta-analysis of randomized controlled trials. Pharmacological Research, 166, 105512. https://doi.org/10.1016/j.phrs.2021.105512
   PubMed Web of Science ®Google Scholar
• Ye, F., Wen, J., Yang, A., Wang, Y., Li, N., Yu, P., Wei, W., & Tang, J. (2022). The influence of hormone therapy on secondary diabetes mellitus in breast cancer: A meta-analysis. Clinical Breast Cancer, 22(1), e48–e58. https://doi.org/10.1016/j.clbc.2021.06.014
   PubMed Web of Science ®Google Scholar